

**Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort**


S.M. Laville, M. Metzger, B. Stengel, C. Jacquelinet, C. Combe, D. Fouque, M. Laville, L. Frimat, C. Ayav, E. Speyer, B.M. Robinson, Z.A. Massy, S. Liabeuf

*British Journal of Clinical Pharmacology*


Corresponding author:

Bénédicte Stengel  
Director, Inserm U1018, Team 5  
UPS-UVSQ, CESP, Centre for Epidemiology and Population Health  
EpReC Team, Renal and Cardiovascular Epidemiology  
16, avenue P. Vaillant Couturier  
94 807 Villejuif cedex  
France  
Phone: + 33 1 4559 5039  
E-mail: benedicte.stengel@inserm.fr


**a. Using the CKD-EPI equation to estimate kidney function**



**b. Using the de-indexed CKD-EPI equation to estimate kidney function**



**c. Using the Cockcroft-Gault equation to estimate kidney function**



**Supplementary Figure 3:** Percentages of contraindicated, inappropriately high dose or inappropriate prescriptions (i.e. contraindicated or inappropriately high dose), by CKD stage. a. Using the CKD-EPI equation to estimate renal function b. Using the de-indexed CKD-EPI equation to estimate renal function c. Using the Cockcroft-Gault equation to estimate renal function. These analyses were restricted to the 2941 patients with data on weight and height.